Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06367361Phase 2Not Yet Recruiting

One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole in Chronic Fascioliasis

Role: collaborator

NCT06565507Phase 2Not Yet Recruiting

Oxfendazole in Mild Parenchymal Brain Cysticercosis

Role: collaborator

NCT03435718Phase 2Not Yet Recruiting

Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults

Role: lead

All 3 trials loaded